1. Rutherford RB. Vascular surgery, ELSEVIER Saunders, 2005, ISBN 0-7216-0299-1.
2. Caprini J, Wentworth D. Venous thrombosis prophylaxis. Venous and Lymphatic Diseases edited by N. Labropoulos and G. Stansby, Taylor&Francis, 2006, ISBN-13:978-0-8247-2923-3; 173–204.
3. Gainor C, Vanscoy G, Niccolai C et al. Pharmacologic and liability considerations of therapeutic interchange with low-molecular-weight heparins. Hospital Pharmacy 2003; 38 (7): 652–8.
4. Geerts W, Berqvist D, Pineo G et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 381S–453.
5. Kearon C, Kahn S, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 354S–545.
6. Harrington R, Becker R, Cannon P et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes:  American College of Chest Physicians  Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl): 670S–707.
7. Явелов И.С. Препараты низкомолекулярного гепарина: основные свойства и возможности создания аналогов. Клин. фармакол. и тер. 2010; 19: 56–63.
8. Blossom D, Kallen A, Patel P et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674–84.
9. Enoxaparin now affected by heparin contaminant. Hughes S. http://www.the-heart.org/articIe/859795.do
10. Kishimoto Т, Viswanathan K, Ganguly T et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457–67.
11. Gray E, Mulloy B. Biosimilar low molecular heparin products. J Thromb Haemost 2009; 7: 1218–21.
12. Planes A. Review of bemiparin sodium-a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother 2003; 4 (9): 1551–61.
13. Falkon L, Saenz-Campos D, Antonijoan R et al. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb Res 1995; 78: 77–86.
14. Falkon L, Bayes M, Frontera G et al. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers- a dose-finding study within the therapeutical range. Thromb Haemost 1997; 77: 133–6.
15. Collignon F, Frydman A, Caplain et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins- dalteparin, enoxaparin, nadroparin- administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995, 73: 630–40.
16. Eriksson BI, Soderberg K, Widlund L et al. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995, 73: 398–401.
17. Breddin HK. Reviparin sodium- a new low molecular weight heparin. Expert Opin Pharmacother 2002; 3: 173–82.
18. Santamaria A, Juarez S, Reche A et al. Low-molecular weight heparin, Bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: THE ESFERA study. Clinical Practice 2006; 60: 518–25.
19. Gerotziafas GT, Dupont C, Spyropoulos AC et al. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb Haemost 2009; 102 (1): 42–8.
20. Borrell M, Antonijoan RM, Ortin R et al. Pharmacokinetic profiles of two LMWH: Bemiparin 3,500 IU and Enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb Haemost 2001; 86 (Suppl): CD3578 (abstract).
21. Depasse F, Gonzalez De Suso M, Lagoutte I et al. Comparative study of the pharmacokinetic profiles of two LMWH-Bemiparin (3,500 IU anti-Xa) and Tinzaparin (4,500 IU anti-Xa) – administered subcutaneously to healthy male volunteers. Thromb Res 2003; 109: 109–17.
22. Kakkar VV, Howes J, Sharma V et al: A comparative, double-blind, randomized trial of new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost 2000, 83: 523–9.
23. Navarro-Quilis A, Castellet E, Rocha E et al. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J Thromb Haemost 2003, 1: 425–32.
24. Planes A, Vochelle M, Fagola M et al. Comparison of two low molecular weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis 1998; 9: 499–505.
25. Planes A, Vochelle N, Gonzalez De Suso MJ et al. Profilaxis antitrombotica poscirurgia ortopedica con bemiparina, heparina de bajo peso molecular de segunda generacion. Rev Anestesiol Reanim 2001, 48: 258–63.
26. Moreno Gonzalez E, FontcubertaJ, De La Llama F. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology, 1996; 43: 744–7.

В.Ю.Богачев

Клиника факультетской хирургии РГМУ